Jade Biosciences JBIO Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Climb Global Solutions, Inc.CLMB

$1.79M-18.5%

Travere Therapeutics, Inc.TVTX

$15.58M-25.9%

Vor BiopharmaVOR

$2.94M-90.5%

AnaptysBio, Inc.ANAB

$13.61K-99.9%

Avalo TherapeuticsAVTX

$242K-64.4%

Aclaris TherapeuticsACRS

$1.85M-21.8%

FAQ

What is Jade Biosciences's operating lease liabilities (total)?

Jade Biosciences (JBIO) reported operating lease liabilities (total) of $808K in Q1 2026.

How has Jade Biosciences's operating lease liabilities (total) changed year-over-year?

Jade Biosciences's operating lease liabilities (total) increased by 159.0% year-over-year, from $312K to $808K.

What is the long-term trend for Jade Biosciences's operating lease liabilities (total)?

Over 4 years (2021 to 2025), Jade Biosciences's operating lease liabilities (total) has grown at a 10.3% compound annual growth rate (CAGR), from $574K to $851K.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.